Health & Environmental Research Online (HERO)


Print Feedback Export to File
8328392 
Journal Article 
Targeting the PI3K-AKT-mTOR singnaling network in cancer 
Khan, KH; Yap, TA; Yan, L; Cunningham, D 
2013 
Yes 
Aizheng
ISSN: 1000-467X 
32 
5 
253-265 
English 
The phosphoinositide 3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway is a frequently hyperactivated pathway in cancer and is important for tumor cell growth and survival. The development of targeted therapies against mTOR, a vital substrate along this pathway, led to the approval of allosteric inhibitors, including everolimus and temsirolimus, for the treatment of breast, renal, and pancreatic cancers. However, the suboptimal duration of response in unselected patients remains an unresolved issue. Numerous novel therapies against critical nodes of this pathway are therefore being actively investigated in the clinic in multiple tumour types. In this review, we focus on the progress of these agents in clinical development along with their biological rationale, the need of predictive biomarkers and various combination strategies, which will be useful in counteracting the mechanisms of resistance to this class of drugs. 
Molecular therapeutics; PI3K-AKT-mTOR; PTEN; RTK; Signaling pathways